List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7351514/publications.pdf Version: 2024-02-01



ΖΟΙΤΑΝ ΜΑΡΙ

#	Article	IF	CITATIONS
1	Identifying true brain interaction from EEG data using the imaginary part of coherency. Clinical Neurophysiology, 2004, 115, 2292-2307.	1.5	1,529
2	The Parkinson Progression Marker Initiative (PPMI). Progress in Neurobiology, 2011, 95, 629-635.	5.7	1,278
3	Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease. Nature Medicine, 2018, 24, 931-938.	30.7	712
4	Association of Cerebrospinal Fluid β-Amyloid 1-42, T-tau, P-tau <sub>181</sub> , and α-Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson Disease. JAMA Neurology, 2013, 70, 1277-87.	9.0	318
5	A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease. JAMA Neurology, 2014, 71, 543.	9.0	312
6	Tourette syndrome deep brain stimulation: A review and updated recommendations. Movement Disorders, 2015, 30, 448-471.	3.9	236
7	Effect of Creatine Monohydrate on Clinical Progression in Patients With Parkinson Disease. JAMA - Journal of the American Medical Association, 2015, 313, 584.	7.4	192
8	Efficacy and Safety of Deep Brain Stimulation in Tourette Syndrome. JAMA Neurology, 2018, 75, 353.	9.0	186
9	National randomized controlled trial of virtual house calls for Parkinson disease. Neurology, 2017, 89, 1152-1161.	1.1	169
10	Widespread abnormality of the γ-aminobutyric acid-ergic system in Tourette syndrome. Brain, 2012, 135, 1926-1936.	7.6	166
11	Diffusion, spread, and migration of botulinum toxin. Movement Disorders, 2013, 28, 1775-1783.	3.9	147
12	Asymmetric spatiotemporal patterns of event-related desynchronization preceding voluntary sequential finger movements: a high-resolution EEG study. Clinical Neurophysiology, 2005, 116, 1213-1221.	1.5	142
13	The past, present, and future of telemedicine for Parkinson's disease. Movement Disorders, 2014, 29, 871-883.	3.9	141
14	Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease. JAMA Neurology, 2021, 78, 312.	9.0	83
15	Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression. JAMA - Journal of the American Medical Association, 2021, 326, 926.	7.4	80
16	Association Between Change in Body Mass Index, Unified Parkinson's Disease Rating Scale Scores, and Survival Among Persons With Parkinson Disease. JAMA Neurology, 2016, 73, 321.	9.0	77
17	Improved prediction of outcome in Parkinson's disease using radiomics analysis of longitudinal DAT SPECT images. NeuroImage: Clinical, 2017, 16, 539-544.	2.7	76
18	Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. Lancet Neurology, The, 2021, 20, 182-192.	10.2	74

#	Article	IF	CITATIONS
19	Global Survey on Telemedicine Utilization for Movement Disorders During the <scp>COVID</scp> â€19 Pandemic. Movement Disorders, 2020, 35, 1701-1711.	3.9	73
20	Deep Brain Stimulation Targeting the Fornix for Mild Alzheimer Dementia (the ADvance Trial): A Two Year Follow-up Including Results of Delayed Activation. Journal of Alzheimer's Disease, 2018, 64, 597-606.	2.6	69
21	Application of texture analysis to DAT SPECT imaging: Relationship to clinical assessments. NeuroImage: Clinical, 2016, 12, e1-e9.	2.7	59
22	Critical Appraisal of Amyloid Lowering Agents in AD. Current Neurology and Neuroscience Reports, 2021, 21, 39.	4.2	57
23	The International Deep Brain Stimulation Registry and Database for Gilles de la Tourette Syndrome: How Does It Work?. Frontiers in Neuroscience, 2016, 10, 170.	2.8	55
24	Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits. Movement Disorders, 2015, 30, 1885-1892.	3.9	52
25	National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers. Telemedicine Journal and E-Health, 2016, 22, 590-598.	2.8	47
26	Dystonia and Tremor. Neurology, 2021, 96, e563-e574.	1.1	46
27	The longitudinal impact of depression on disability in Parkinson disease. International Journal of Geriatric Psychiatry, 2016, 31, 458-465.	2.7	43
28	Psychogenic palatal tremor. Movement Disorders, 2006, 21, 274-276.	3.9	39
29	Clinical and demographic characteristics related to onset site and spread of cervical dystonia. Movement Disorders, 2016, 31, 1874-1882.	3.9	39
30	Dopamine transporter availability reflects gastrointestinal dysautonomia in early Parkinson disease. Parkinsonism and Related Disorders, 2018, 55, 8-14.	2.2	37
31	Implementation of Telemedicine for Urgent and Ongoing Healthcare for Patients with Parkinson's Disease During the COVID-19 Pandemic: New Expectations for the Future. Journal of Parkinson's Disease, 2020, 10, 911-913.	2.8	35
32	Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson's disease. Npj Parkinson's Disease, 2019, 5, 30.	5.3	32
33	Neuropsychiatric Complications of Parkinson Disease Treatments: Importance of Multidisciplinary Care. American Journal of Geriatric Psychiatry, 2016, 24, 1171-1180.	1.2	28
34	Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort. Journal of the Neurological Sciences, 2017, 377, 137-143.	0.6	27
35	Altering Effort Costs in Parkinson's Disease with Noninvasive Cortical Stimulation. Journal of Neuroscience, 2015, 35, 12287-12302.	3.6	26
36	Neural Correlates of Freezing of Gait in Parkinson's Disease: An Electrophysiology Mini-Review. Frontiers in Neurology, 2020, 11, 571086.	2.4	26

#	Article	IF	CITATIONS
37	Intact implicit probabilistic sequence learning in obstructive sleep apnea. Journal of Sleep Research, 2012, 21, 396-401.	3.2	25
38	Betting on DBS: Effects of subthalamic nucleus deep brain stimulation on risk taking and decision making in patients with Parkinson's disease Neuropsychology, 2015, 29, 622-631.	1.3	24
39	Unique white matter structural connectivity in early-stage drug-naive Parkinson disease. Neurology, 2020, 94, e774-e784.	1.1	24
40	What predicts falls in Parkinson disease?. Neurology: Clinical Practice, 2018, 8, 214-222.	1.6	23
41	Uptake of telehealth in Parkinson's disease clinical care and research during the COVID-19 pandemic. Parkinsonism and Related Disorders, 2021, 86, 97-100.	2.2	23
42	Telemedicine Use for Movement Disorders: A Global Survey. Telemedicine Journal and E-Health, 2018, 24, 979-992.	2.8	22
43	An Update and Review of the Treatment of Myoclonus. Current Neurology and Neuroscience Reports, 2015, 15, 512.	4.2	21
44	Cognitive impairment in Parkinson's disease: Association between patient-reported and clinically measured outcomes. Parkinsonism and Related Disorders, 2016, 33, 107-114.	2.2	21
45	OnabotulinumtoxinA and AbobotulinumtoxinA Dose Conversion: A Systematic Literature Review. Movement Disorders Clinical Practice, 2016, 3, 109-115.	1.5	21
46	Personality and reported quality of life in Parkinson's disease. International Journal of Geriatric Psychiatry, 2017, 32, 324-330.	2.7	19
47	A mixed treatment comparison to compare the efficacy and safety of botulinum toxin treatments for cervical dystonia. Journal of Neurology, 2016, 263, 772-780.	3.6	18
48	Digital phenotyping in Parkinson's disease: Empowering neurologists for measurement-based care. Parkinsonism and Related Disorders, 2020, 80, 35-40.	2.2	18
49	Telemedicine and Deep brain stimulation - Current practices and recommendations. Parkinsonism and Related Disorders, 2021, 89, 199-205.	2.2	18
50	Clinico-Pathological Correlation in Progressive Ataxia and Palatal Tremor: A Novel Tauopathy. Movement Disorders Clinical Practice, 2014, 1, 50-56.	1.5	17
51	Brainstem Pathologies Correlate With Depression and Psychosis in Parkinson's Disease. American Journal of Geriatric Psychiatry, 2021, 29, 958-968.	1.2	17
52	The Disease Modification Conundrum in Parkinson's Disease: Failures and Hopes. Frontiers in Aging Neuroscience, 2022, 14, 810860.	3.4	17
53	The Unique and Combined Effects of Apathy and Depression on Cognition in Parkinson's Disease. Journal of Parkinson's Disease, 2015, 5, 351-359	2.8	16
54	Validation of an Ambulatory Capacity Measure in Parkinson Disease: A Construct Derived from the Unified Parkinson's Disease Rating Scale. Journal of Parkinson's Disease, 2015, 5, 67-73.	2.8	16

ZOLTAN MARI

#	Article	IF	CITATIONS
55	Necessity and feasibility of remote tele-programming of deep brain stimulation systems in Parkinson's disease. Parkinsonism and Related Disorders, 2022, 96, 38-42.	2.2	15
56	Myoclonusâ€dystonia and Silver–Russell syndrome resulting from maternal uniparental disomy of chromosome 7. Clinical Genetics, 2013, 84, 368-372.	2.0	14
57	Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias. Parkinsonism and Related Disorders, 2018, 47, 50-56.	2.2	14
58	Minimal clinically important change in patients with cervical dystonia: Results from the CD PROBE study. Journal of the Neurological Sciences, 2019, 405, 116413.	0.6	14
59	Mapping autonomic, mood and cognitive effects of hypothalamic region deep brain stimulation. Brain, 2021, 144, 2837-2851.	7.6	14
60	Changes in Verbal Fluency in Parkinson's Disease. Movement Disorders Clinical Practice, 2017, 4, 84-89.	1.5	13
61	Integration and Extension of Specialty Mental Healthcare Services to Community Practice in Parkinson Disease. American Journal of Geriatric Psychiatry, 2019, 27, 712-719.	1.2	13
62	Mind the gap: Inequalities in mental health care and lack of social support in Parkinson disease. Parkinsonism and Related Disorders, 2021, 93, 97-102.	2.2	13
63	Effect of STN DBS on vesicular monoamine transporter 2 and glucose metabolism in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 64, 235-241.	2.2	12
64	No Sex Differences in Use of Dopaminergic Medication in Early Parkinson Disease in the US and Canada - Baseline Findings of a Multicenter Trial. PLoS ONE, 2014, 9, e112287.	2.5	12
65	Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium. Frontiers in Neurology, 2021, 12, 805135.	2.4	12
66	The Preoperative Neurological Evaluation. Neurohospitalist, The, 2013, 3, 209-220.	0.8	11
67	An Acute Application of Cerebellar Transcranial Direct Current Stimulation Does Not Improve Motor Performance in Parkinson's Disease. Brain Sciences, 2020, 10, 735.	2.3	11
68	Perception of Phosphenes and Flashed Alphabetical Characters is Enhanced by Single-Pulse Transcranial Magnetic Stimulation of Anterior Frontal Lobe: The Thalamic Gate Hypothesis. Perception, 2008, 37, 375-388.	1.2	9
69	Mobility, mood and site of care impact health related quality of life in Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, 274-279.	2.2	9
70	Domainâ€specific cognitive impairment in nonâ€demented Parkinson's disease psychosis. International Journal of Geriatric Psychiatry, 2018, 33, e131-e139.	2.7	9
71	Onset and Remission of Psychosis in Parkinson's Disease: Pharmacologic and Motoric Markers. Movement Disorders Clinical Practice, 2018, 5, 31-38.	1.5	9
72	Suicide and Lewy body dementia: Report of a Lewy body dementia association working group. International Journal of Geriatric Psychiatry, 2021, 36, 373-382.	2.7	9

#	Article	IF	CITATIONS
73	Global Variability in Deep Brain Stimulation Practices for Parkinson's Disease. Frontiers in Human Neuroscience, 2021, 15, 667035.	2.0	9
74	Long-Term Application of Cerebellar Transcranial Direct Current Stimulation Does Not Improve Motor Learning in Parkinson's Disease. Cerebellum, 2022, 21, 333-349.	2.5	9
75	Videoconferencing Software Options for Telemedicine: A Review for Movement Disorder Neurologists. Frontiers in Neurology, 2021, 12, 745917.	2.4	9
76	Gait function and locus coeruleus Lewy body pathology in 51 Parkinson's disease patients. Parkinsonism and Related Disorders, 2016, 33, 102-106.	2.2	8
77	Neuroscience20 (BRAIN20, SPINE20, and MENTAL20) Health Initiative: A Global Consortium Addressing the Human and Economic Burden of Brain, Spine, and Mental Disorders Through Neurotech Innovations and Policies. Journal of Alzheimer's Disease, 2021, 83, 1563-1601.	2.6	8
78	North American survey on impact of the COVID-19 pandemic shutdown on DBS care. Parkinsonism and Related Disorders, 2021, 92, 41-45.	2.2	8
79	Remote measurement and home monitoring of tremor. Journal of the Neurological Sciences, 2022, 435, 120201.	0.6	7
80	Impact of Depression on Progression of Impairment and Disability in Early Parkinson's Disease. Movement Disorders Clinical Practice, 2015, 2, 371-378.	1.5	6
81	Clinicopathological Correlates in a <i><scp>PRNP</scp></i> P102L Mutation Carrier with Rapidly Progressing Parkinsonismâ€Dystonia. Movement Disorders Clinical Practice, 2016, 3, 355-358.	1.5	6
82	Dementia with Lewy bodies: emerging drug targets and therapeutics. Expert Opinion on Investigational Drugs, 2021, 30, 603-609.	4.1	6
83	Anxiety in Parkinson's Disease: A Systematic Review of Neuroimaging Studies. Journal of Neuropsychiatry and Clinical Neurosciences, 2021, 33, 280-294.	1.8	6
84	REM Sleep Behavior and Motor Findings in Parkinson's Disease: A Cross-sectional Analysis. Tremor and Other Hyperkinetic Movements, 2014, 4, 245.	2.0	6
85	Thalamic post-inhibitory bursting occurs in patients with organic dystonia more often than controls. Brain Research, 2013, 1541, 81-91.	2.2	5
86	Evaluating and managing sleep disorders in the parkinson's disease clinic. Basal Ganglia, 2016, 6, 165-172.	0.3	5
87	Perceived Treatment Status of Fluctuations in Parkinson Disease Impacts Suicidality. American Journal of Geriatric Psychiatry, 2018, 26, 700-710.	1.2	5
88	Timing of the Sense of Volition in Patients With Schizophrenia. Frontiers in Neuroscience, 2020, 14, 574472.	2.8	5
89	Hippocampal correlates of episodic memory in Parkinson's disease: A systematic review of magnetic resonance imaging studies. Journal of Neuroscience Research, 2021, 99, 2097-2116.	2.9	5
90	How Should Pushing Off or the Use of Assistive Devices Be Incorporated in the Timed Up and Go for Persons With Parkinson Disease?. Archives of Physical Medicine and Rehabilitation, 2015, 96, 1728-1732.	0.9	4

ZOLTAN MARI

#	Article	IF	CITATIONS
91	Application of pattern recognition framework for quantification of Parkinson's disease in DAT SPECT imaging. , 2014, , .		2
92	Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias. Parkinsonism and Related Disorders, 2018, 53, 108-109.	2.2	1
93	Long-term Botulinum toxin therapy for focal hand dystonia and reasons for discontinuation. International Journal of Surgery, 2013, 11, 657.	2.7	0
94	Clinical Reasoning: A 57-year-old man with jaw spasms. Neurology, 2013, 80, e104-7.	1.1	0
95	Poster 350 A Random Effect Mixed Treatment Comparison (MTC) to Compare the Efficacy of Botulinum Toxin Type A Treatments for Cervical Dystonia. PM and R, 2014, 6, S307.	1.6	0
96	Clinical relevance of treatment with onabotulinumtoxina in patients with cervical dystonia: Results from the cd probe study. Toxicon, 2016, 123, S20.	1.6	0
97	S94 Update on technological advancements in invasive neurophysiological activity monitoring and deep-brain stimulation. Clinical Neurophysiology, 2017, 128, e209.	1.5	0
98	Remission of Gilles de la Tourette Syndrome after Heat-Induced Dehydration. International Journal of Physical Medicine & Rehabilitation, 2018, 06, .	0.5	0
99	Genetic Mutations and Deep Brain Stimulation. , 2020, , 59-64.		0
100	Resting state functional connectivity in levodopa non responsive Parkinson's disease patients with freezing of gait. Parkinsonism and Related Disorders, 2020, 79, e8.	2.2	0